Excitement over the potentially broad health benefits of glucagon-like peptide 1 (GLP-1) agonists and other new mechanisms for obesity and cardiovascular/metabolic conditions is spreading across the sector. The topic dominated the third quarter conference calls of the two market leaders in the therapeutic area, Novo Nordisk A/S and Eli Lilly and Company, but obesity was also a hot topic of discussion during investor calls by Pfizer Inc., Amgen, Inc. and AstraZeneca PLC, companies that are all vying to get into the lucrative market.
Obesity Stole The Q3 Show
Novo Nordisk’s Wegovy/Ozempic and Lilly’s Mounjaro were third quarter standouts, but the exploding obesity category was a theme across many of the big pharma company earnings calls.
